Katherine K. Nishimura

Katherine K. Nishimura

Auto-generated profile, based on publicly available information

Katherine K. Nishimura

Cancer Research and Biostatistics, Seattle, WA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2019 in Nature
Verified
Journal Article
Closed access
PDF file
GWGenevieve L. Wojcik
Genevieve L. Wojcik
MGMariaelisa Graff
Mariaelisa Graff
KNKatherine K. Nishimura
Katherine K. Nishimura
RTRan Tao
Ran Tao
JHJeffrey Haessler
Jeffrey Haessler
CCChristopher S. Carlson
Christopher S. Carlson

1 August 2013 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KNKatherine K. Nishimura
Katherine K. Nishimura
JGJoshua M. Galanter
Joshua M. Galanter
LRLindsey A. Roth
Lindsey A. Roth
SOSam S. Oh
Sam S. Oh
NTNeeta Thakur
Neeta Thakur
EBEsteban G. Burchard
Esteban G. Burchard
Rationale: Air pollution is a known asthma trigger and has been associated with short-term asthma symptoms, airway inflammation, decreased lung function, and reduced response to asthma rescue medications. Objectives: To assess a causal relationship between air pollution and childhood asthma using data that address temporality by estimating air pollution exposures before the development of asthma and to establish the generalizability of the association by studying diverse racial/ethnic populations in different geographic regions. Methods: This study included Latino (n = 3,343) and African American (n = 977) participants with and without asthma from five urban regions in the mainland United States and Puerto Rico. Residential history and data from local ambient air monitoring stations were used to estimate average annual exposure to five air pollutants: ozone, nitrogen dioxide (NO2), sulfur dioxide, particulate matter not greater than 10 μm in diameter, and particulate matter not greater than 2.5 μm in diameter. Within each region, we performed logistic regression to determine the relationship between early-life exposure to air pollutants and subsequent asthma diagnosis. A random-effects model was used to combine the region-specific effects and generate summary odds ratios for each pollutant. Measurements and Main Results: After adjustment for confounders, a 5-ppb increase in average NO2 during the first year of life was associated with an odds ratio of 1.17 for physician-diagnosed asthma (95% confidence interval, 1.04–1.31). Conclusions: Early-life NO2 exposure is associated with childhood asthma in Latinos and African Americans. These results add to a growing body of evidence that traffic-related pollutants may be causally related to childhood asthma.

1 January 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
Maria Pino-YanesMaria Pino-Yanes
Maria Pino-Yanes
NTNeeta Thakur
Neeta Thakur
CGChristopher R. Gignoux
Christopher R. Gignoux
JGJoshua M. Galanter
Joshua M. Galanter
LRLindsey A. Roth
Lindsey A. Roth
EBEsteban G. Burchard
Esteban G. Burchard

28 January 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
KNKatherine K. Nishimura
Katherine K. Nishimura
BBBart Barlogie
Bart Barlogie
FRFrits van Rhee
Frits van Rhee
MZMaurizio Zangari
Maurizio Zangari
Brian WalkerBrian Walker
Brian Walker
GMGareth John Morgan
Gareth John Morgan
As multiple myeloma (MM) treatments evolve, frequent updates are required to monitor the long-term effect of changes in approach. Traditionally, MM is considered an incurable disease, with most patients eventually relapsing. However, improvements in treatments has raised the possibility that MM might be functionally curable. To examine improvements in long-term survival, we followed 4329 patients with newly diagnosed MM treated with autologous stem cell transplantation (ASCT) at the University of Arkansas for Medical Sciences from 1989 through 2018. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier analysis, Cox proportional hazards models, relative survival analysis, and cure modeling among different time periods, risk groups, and demographic traits. Steady improvements in OS were found, with patients treated in 2014 or later having superior OS (hazard ratio, 0.35; 95% confidence interval [CI], 0.27-0.45) and reduced excess risk for MM death (relative excess risk, 0.30; 95% CI, 0.22-0.41) compared with patients treated in 1997 or earlier. Patients treated during intervening time periods often had intermediate survival, but trends in OS, PFS, and landmarked analyses were inconsistent. Cure models support the potential for cure, ranging from 6.3% to 31.3%, depending on the year of treatment, with 10.0% to 18.6% of patients achieving their normal life expectancy across multiple periods. There was some evidence of reductions in early mortality within 3 years of diagnosis, longer complete response (CR) duration, and reductions in relapse after achieving CR. However, results differed depending on age, risk group, and cytogenetic characteristics.

11 August 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
DVDiana Merino Vega
Diana Merino Vega
KNKatherine K. Nishimura
Katherine K. Nishimura
NZNévine Zariffa
Névine Zariffa
JTJeffrey C. Thompson
Jeffrey C. Thompson
AHAntje Hoering
Antje Hoering
JAJeff Allen
Jeff Allen
PURPOSE: As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in monitoring response to ICI, but uncertainty exists in the generalizability of these studies. Here, the role of ctDNA for monitoring response to ICI is assessed through a standardized approach by assessing clinical trial data from five independent studies. PATIENTS AND METHODS: Patient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy. CtDNA levels were measured using different ctDNA assays across the studies. Maximum variant allele frequencies were calculated using all somatic tumor-derived variants in each unique patient sample to correlate ctDNA changes with overall survival (OS) and progression-free survival (PFS). RESULTS: We observed strong associations between reductions in ctDNA levels from on-treatment liquid biopsies with improved OS (OS; hazard ratio, 2.28; 95% CI, 1.62 to 3.20; P < .001) and PFS (PFS; hazard ratio 1.76; 95% CI, 1.31 to 2.36; P < .001). Changes in the maximum variant allele frequencies ctDNA values showed strong association across different outcomes. CONCLUSION: In this pooled analysis of five independent clinical trials, consistent and robust associations between reductions in ctDNA and outcomes were found across multiple end points assessed in patients with non–small-cell lung cancer treated with an ICI. Additional tumor types, stages, and drug classes should be included in future analyses to further validate this. CtDNA may serve as an important tool in clinical development and an early indicator of treatment benefit.

1 June 2009 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
CXChang Xu
Chang Xu
BSBoris E. Shmukler
Boris E. Shmukler
KNKatherine Nishimura
Katherine Nishimura
EKElzbieta Kaczmarek
Elzbieta Kaczmarek
SRSandro Rossetti
Sandro Rossetti
SASeth L. Alper
Seth L. Alper
Flow-induced cytosolic Ca2+Cai2+signaling in renal tubular epithelial cells is mediated in part through P2 receptor (P2R) activation by locally released ATP. The ability of P2R to regulate salt and water reabsorption has suggested a possible contribution of ATP release and paracrine P2R activation to cystogenesis and/or enlargement in autosomal dominant polycystic kidney disease (ADPKD). We and others have demonstrated in human ADPKD cyst cells the absence of flow-induced Cai2+signaling exhibited by normal renal epithelial cells. We now extend these findings to primary and telomerase-immortalized normal and ADPKD epithelial cells of different genotype and of both proximal and distal origins. Flow-induced elevation of Cai2+concentration ([Ca2+]i) was absent from ADPKD cyst cells, but in normal cells was mediated by flow-sensitive ATP release and paracrine P2R activation, modulated by ecto-nucleotidase activity, and abrogated by P2R inhibition or extracellular ATP hydrolysis. In contrast to the elevated ATP release from ADPKD cells in static isotonic conditions or in hypotonic conditions, flow-induced ATP release from cyst cells was lower than from normal cells. Extracellular ATP rapidly reduced thapsigargin-elevated [Ca2+]iin both ADPKD cyst and normal cells, but cyst cells lacked the subsequent, slow, oxidized ATP-sensitive [Ca2+]irecovery present in normal cells. Telomerase-immortalized cyst cells also exhibited altered CD39 and P2X7 mRNA levels. Thus the loss of flow-induced, P2R-mediated Cai2+signaling in human ADPKD cyst epithelial cells was accompanied by reduced flow-sensitive ATP release, altered purinergic regulation of store-operated Ca2+entry, and altered expression of gene products controlling extracellular nucleotide signaling.